Can the US Launch of NVO's Wegovy Pill Reignite Momentum in 2026?

Key Takeaways NVO launched the once-daily Wegovy pill in the U.S., the first-ever GLP-1 obesity treatment in oral form.NVO sees the pill as a way to regain lost market share after injectable Wegovy sales slowed in 2025.NVO's tiered pricing and broad rollout strategy aim to curb compounded use and lift Wegovy sales in 2026.Shares of Novo Nordisk (NVO) jumped 5.2% on Monday and about 4% in the pre-market hours today as investors cheered the U.S. launch of its newly approved Wegovy pill (once-daily oral semagl ...